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Background: Serum pepsinogen (PG) levels are valuable in the diagnosis of gastric diseases. However, PG levels are
affected by many factors such as the area and race. This study aimed to investigate serum PG levels in patients
with different gastric diseases who were Chinese Han people in Hunan Province, midsouth China.
Methods: A total of 248 gastric disease patients and 34 healthy controls were enrolled. The patients included those
with non-atrophic and chronic atrophic gastritis, gastric and duodenal ulcer, early and advanced gastric cancer.
Serum PG I and II levels were detected by Biohit ELISA kit (Finland), and PG I/II ratio was calculated. Differences in
patients with gastric disease and healthy controls were analyzed using paired t-test.
Results: Compared with controls, patients with early and advanced gastric cancer had a significantly lower PG I
level and PG I/II ratio (p <0.005). In contrast, patients with gastric and duodenal ulcer had a significantly higher PG I
level (p <0.005). Compared with atrophic gastritis patients, patients with early and advanced carcinoma of the
stomach had a significantly lower PG I/II ratio (p < 0.001). Combination of the cut-off levels of PG I (70 μg/L)
and PG I/II ratio (6) provided 62.1% sensitivity of and 94.2% specificity for the diagnosis of gastric cancer.
Conclusions: Decreased PG I level and PG I/II ratio are risk factors for gastric cancer. Combined use of serum PG I
level and PG I/II ratio may help the early diagnosis of gastric cancer.
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Pepsinogens (PG) are aspartic proteinases which are
mainly secreted by gastric cells. PG can be classified into
two biochemically and immunologically distinct types:
pepsinogen I (PGI) and pepsinogen II (PGII). PG I is se-
creted only from the gastric fundic mucosa, while PGII
is secreted from the cardiac, fundic, and antral mucosa
of the stomach, and also from the duodenal mucosa
[1,2]. PGs are also released into the circulation and it is
widely accepted that serum PG level reflects the func-
tional and morphologic status of stomach mucosa. Human
pepsinogens have a diagnostic value for various gastroduo-
denal disorders, especially for peptic ulcer, atrophic gastri-
tis and gastric cancer [3-8]. The pepsinogen I/II ratio can* Correspondence: guiyingzhang1@126.com
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reproduction in any medium, provided the orprovide even better information on the extent of chronic
gastritis [4].
Gastric cancer is the second leading cause of cancer-
related death in the world. However, the risk of gastric
cancer varies among the countries and populations in
the world. High risk areas include Korea, Japan and
China [9]. When diagnosed at an early stage, 5-year sur-
vival rate for gastric cancer exceeds 90%, but the 5-year
survival rates are below 50% when diagnosed at an ad-
vanced stage [10]. Thus, it is necessary to diagnose gas-
tric cancer at an early stage to reduce the morbidity and
mortality from gastric cancer.
Atrophic gastritis is a well-recognized high-risk condi-
tion for developing gastric cancer. The “gold standard” for
the diagnosis of gastric atrophy is the histological study of
biopsies obtained during an upper gastrointestinal endos-
copy, an invasive method hardly suitable for population
screening [11]. Recent reports showed that human serumLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eases, including gastric atrophy and gastric cancer [3-8].
In addition, the test for serum PG as a marker for chronic
atrophic gastritis has been incorporated into gastric cancer
screening programs, on a trial basis, to identify people
who would benefit from gastric cancer screening [12,13].
However, PG levels are affected by many factors such
as the area, race, age, gender, height, body weight, body
surface area, smoking, drinking habits and Helicobacter
pylori infection [3,4,7]. Unfortunately, few studies have
examined serum PG changes in patients with different
gastric diseases in midsouth China. Therefore, to provide
a valuation of serum PG levels for the survey of gastric
cancer in this area, in the present study we measured
serum PG I and PG II levels in 34 healthy controls and




The subjects were enrolled at the Department of Gastro-
enterology, Xiangya Hospital, Central South University
from September 2005 to August 2007. They included
248 patients (163 men) with a mean age of 52.3 ± 12.3
years (range 19-80 years) who had upper abdominal
complaints and evidence of gastroduodenal disorder, and
34 healthy controls (19 men) with a mean age of 52.4 ±
15.1 years (range 29-77 years) who had no upper abdom-
inal complaints or evidence of gastroduodenal disorder
and liver diseases. All of them were Chinese Han people
in Hunan Province.
The study protocol was approved by the Ethics Committee
of Central South University, and written informed consent
was obtained from all participants.
Determination of serum PG levels
Approximately 5 mL fasting blood was collected from
each participant. The serum was separated and stored
at -20°C until analyzed. PG I and II concentrations
were detected by enzyme-linked immunosorbent assay kit
(Biohit ELISA kit, Finland). The absorbance was measured
by using a microplate spectrophotometer at 450 nm. PG I
and II levels were calculated based on standard curve. The
ratio of PG I/II was then calculated. Each sample was
evaluated twice for each patient, a coefficient of variation
of < 15% was considered acceptable.
Endoscopic and clinicopathological examinations
All subjects underwent a gastroscopy and biopsy. The
biopsies were scored semi-quantitatively by two histopa-
thologists, according to the updated Sydney classification
system. Gastrointestinal endoscopy was performed for
the entire stomach. H. pylori infection was detected by
rapid urease test and anti-H. pylori IgG test as describedpreviously [11], and current H. pylori infection was con-
firmed if both rapid urease test and anti-H. pylori IgG
test gave positive results. Experienced endoscopists per-
formed each examination without knowledge about the
serological data on the study subjects. Based on endo-
scopic examination and histological appearances, the
patients were classified into seven categories as follows: 55
cases of non-atrophic gastritis (NAG), 20 cases of chronic
atrophic gastritis (CAG), 36 cases of gastric ulcer (GU), 31
cases of duodenal ulcer (DU), 69 cases of advanced gastric
cancer (AGC), 13 cases of early gastric cancer (EGC) before
operation and 24 cases with partial gastrectomy for gastric
cancer, one of them with recurrence of gastric cancer.
Statistical analysis
Data were expressed as mean ± SD. Differences in patients
with gastric disease and healthy controls were analyzed
using Student’s t-test. The distribution of variables was
tested by “Kolmogorov-Smirnov”. For normal distribution,
the mean and standard of deviation values were analyzed
for significant difference between the two groups using
Student’s t-test. Otherwise, the median values were ana-
lyzed for significant difference using Mann-Whitney test.
The statistical analysis was performed by using SPSS pro-
gram for Windows version 17.0. p < 0.05 was considered
statistically significant.
Results
Serum PG levels and PGI/II ratio in patients with different
gastric diseases
By ELISA assay we detected serum levels of PG I and PG
II and calculated PG I/II ratio for all subjects (Table 1).
Compared with the normal control group, PG I and PG II
levels and PG I/II ratio showed no statistical significance in
NAG and CAG group (p > 0.05). However, PG I and PG II
levels and PG I/II ratio were significantly higher in patients
with duodenal ulcer than in the controls (p < 0.05). In
addition, serum PGI level and PGI/II ratio were signifi-
cantly lower in patients with early or advanced gastric can-
cer than in the controls and NAG group (p < 0.001), but
there were no significant differences in PG I and PG II
levels and PG I/II ratio between EGC and AGC group.
Compared with CAG patients, serum PGI level was lower
in patients with AGC and PG I/II ratio was lower in pa-
tients with AGC or EGC (p < 0.05). Notably, PG I and PG
II levels were extremely low in the patients with partial
gastrectomy for gastric cancer (p < 0.005), but were abnor-
mally high in one patient with recurrence of gastric cancer
after gastrectomy (Table 1).
Low PG I level and PG I/II ratio could predict gastric
cancer
Next we investigated the optimal cut-off points and per-
formance of PG I level and PG I/II ratio for the diagnosis
Table 1 Serum PG I and II levels in various gastric disorders (n = 282)
Group N PG I (μg/L) PG II (μg/L) PG I/PG II
Healthy controls 34 118.39 ± 47.80 12.39 ± 5.90 11.74 ± 6.23
Non-atrophic gastritis 55 112.46 ± 51.71 12.57 ± 5.98 10.63 ± 5.74
Atrophic gastritis 20 93.63 ± 49.34 10.85 ± 4.58 11.07 ± 5.78
Early gastric cancer 13 71.48 ± 28.78‡▼ 14.22 ± 4.90 5.19 ± 1.70‡†
Advanced gastric cancer 69 53.39 ± 34.03‡† 12.29 ± 5.63 4.88 ± 3.76‡†
Gastric ulcer 36 147.58 ± 57.81▲† 15.60 ± 13.42 14.47 ± 13.02
Duodenal ulcer 31 217.43 ± 51.12‡† 21.90 ± 19.45▲† 18.57 ± 16.63▲†
Gastrectomy 23 40.70 ± 15.38‡* 8.52 ± 4.52 4.43 ± 2.38‡
Recurrence after gastrectomy 1 289.32 65.89 4.39
Data were shown as mean ± SD.
‡p < 0.005, ▲p < 0.05 vs. Healthy controls; †p < 0.005, ▼p < 0.05 vs. NAG; *p < 0.05 vs. CAG.
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criminatory ability did not differ between PG I and PG I/II
values, with areas under the ROC curves of 0.880 and
0.876, respectively (p = 0.28). The optimal PG I cut-off
concentration was 70.1 μg/L, with a sensitivity of 82.1%
and a specificity of 72.5%. The optimal cut-off PG I/II ratio
was 6.0, with a sensitivity of 82.9% and a specificity of 76.8%.
PG I level had positive predictive value of 68.2%, a negative
predictive value of 82.3%, and an accuracy of 77.2%.Table 2 Comparison of frequency of PG levels in non-GC
and GC groups
Variables Non-GC group (%) GC group (%)
Number of subjects 142 82
PG I (μg/L)
≤30 2 (1.4) 27 (32.9)
≤40 2 (1.4) 33 (40.2)
≤50 9 (6.3) 43 (52.4)
≤60 19 (13.4) 47 (57.3)
≤70 25 (17.6) 56 (68.2)
≤80 33 (23.2) 61 (74.3)
≤90 41 (28.9) 67 (81.7)
>90 101 (71.1) 15 (18.3)
PG I/II radio
≤3 2 (1.4) 21 (25.6)
≤4 7 (5.0) 31 (37.8)
≤5 18 (12.7) 43 (52.4)
≤6 25 (17.6) 53 (64.6)
≤7 33 (23.2) 56 (68.3)
≤8 38 (26.8) 61 (74.4)
≤9 49 (34.5) 65 (80.4)
>9 91(64.1) 4 (4.7)
Non-GC group included 55 of non-atrophic gastritis, 20 of atrophic gastritis,
36 of gastric ulcer, 31 of duodenal ulcer. GC group included 13 of early gastric
cancer, 69 of advanced gastric cancer.Using a level of 70 μg/L PG I as a serologic cut-off
for gastric cancer, we found that 68.2% patients with
PG I < 70 μg/L and 31.8% patients with PG I ≥ 70 μg/L
had gastric cancer. Using a cut-off of 6 for PG I/II ra-
tio, we found that 76.8% patients with PG I/II < 6 and
23.2% patients with PG I/II ≥ 6 had tumors. Combining
the two indexes of serum PG I ≤ 70 ug/L and PG I/PGII ≤
6, we found that the diagnostic sensitivity and specificity
of gastric cancer were 62.1% and 94.2%, respectively
(Table 4). These results suggest that low PG I level and
PG I/II ratio are valuable serologic markers for predicting
gastric cancer when used in combination.
The clinical value of serum PG levels in the diagnosis of
peptic ulcer
As shown in Table 1, serum PG I level in the patients
with gastric ulcer and those with duodenal ulcer were
147.58 ± 57.81 μg/L (n = 36) and 217.43 ± 51.12 μg/L
(n = 31), respectively, significantly higher than in the
subjects with endoscopically normal mucosa (118.39 ±
47.8 μg/L). These data suggest that serum PG I level
is useful in the differential diagnosis of gastric cancer
from gastric ulcer, and increased PG I levels is a risk
factor for peptic ulcer.Table 3 Predicting gastric cancer based on serum PG I
level and PG I/II ratio
PG I level PG I/II ratio
Area under the ROC curve 0.880 (0.835-0.925) 0.876 (0.827-0.925)
Optimal cult-off value 70.1 μg/L 6
Sensitivity, % 82.1 82.9
Specificity, % 72.5 76.8
Positive predictive value, % 68.2 64.6
Negative predictive value, % 82.3 82.3
Accuracy, % 77.2 75.8
Figure 1 Characteristic curves of PG I level and PG I/II ratio for
discriminating gastric cancer. The optimal cut-off points of PG I
level and PG I/II ratio were determined by analysis of receiver operating
characteristic (ROC). The discriminatory ability did not differ between
PG I and PG I/II values, with areas under the ROC curves of 0.880 and
0.876, respectively (p = 0.28).
Table 5 Serum PG I level and PG I/II ratio in H. pylori
positive and negative group
Group N (%) PGI (μg/L) PG I/PG II
Hp + 201 (77.9) 174.82 ± 41.73* 6.74 ± 1.72*
Hp - 57 (22.1) 101.23 ± 10.77 10.08 ± 3.31
*p < 0.05 vs. Hp – group.
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Finally, we detected the infection of H. pylori in the sub-
jects. The rate of H. pylori infection was 52.9% (18/34)
in healthy controls, 67.3% (37/55) in superficial gastritis pa-
tients, 80.0% (16/20) in atrophic gastritis patients, 85.4%
(70/82) in gastric cancer patients, and 89.6% (60/67) in
duodenal ulcer patients. The infection rate was significantly
higher in diseased group than in healthy controls (p < 0.01).
In addition, we found that serum PG levels were sig-
nificantly higher in Hp + group than in Hp- group, while
PG I/II ratio was significantly lower in Hp + group than
in Hp- group (p < 0.05, Table 5). There data suggest that
H. pylori infection is associated with increased serum
PG levels.Table 4 Comparison of the diagnostic performance for
gastric cancer based on different values of PG I level and
PG I/II ratio
Sensitivity (%) Specificity (%)
PGI≤ 70 and PGI/PGII≤ 4 40.2 98.5
PGI≤ 70 and PGI/PGII≤ 5 54.8 96.4
PGI≤ 70 and PGI/PGII≤ 6 62.1 94.2
PGI≤ 70 or PGI/PGII≤ 4 68.3 77.1
PGI≤ 70 or PGI/PGII≤ 5 73.1 69.2
PGI≤ 70 or PGI/PGII≤ 6 81.7 64.2Discussion
In this study, our results showed that serum PG I level
and PG I/II ratio decreased in patients with CAG com-
pared with those with NAG, although no statistical sig-
nificance was observed. However, serum PG I level and
PG I/II ratio in patients with advanced gastric cancer
and PG I/II ratio in patients with early gastric cancer
were lower than those with CAG. These results are in
accordance with previous reports [3,4]. Serum PG I con-
centration decreases with the progression of gastric atro-
phy as well as gastric cancer because of the loss of chief
cells in the fundic glands.
By using the ROC curve, we analyzed the correlation
between the diagnostic accuracy based on serum PG
levels with gastroscopy and histologic assessment. The
area under ROC curve (AUC) is used to measure the
ability of each biomarker to differentiate gastric cancer
patients and non gastric cancer patients. The results
showed that low PG I level and low PG I/II ratio
were valuable serologic markers for predicting gastric
cancer, especially low PGI/II ratio was effective par-
ameter for screening individuals at high risk of early
gastric cancer.
Serum PG levels are known to be affected by demo-
graphic factors including sex, age, smoking, drinking,
and dietary habits, PG test methodologies such as radio-
immunoassay or enzyme immunoassay, which could ex-
plain various cut-off values of serum PG profiles in
different populations [14]. For instance, in Japan, the
proposed cut-off points to determine atrophy and gastric
cancer risk are 70 μg/L for PG I and 3.0 for PGI/II ratio
[15]. In European countries, the cut-off values were 25
μg/L for PG I and 3.0 for PG I/II [16]. In a Korean study,
PG I ≤ 70 ng/mL showed sufficient sensitivity (72.4%) but
a low specificity (20.2%), and the sensitivity and specificity
of a PGI/II ratio cut off of ≤ 3 were 59.2-61.7% and 61.0%,
respectively [17]. In addition, different test-systems for
serum PG levels are generally used in different parts of
the world. For example, ELISA is used mainly in Europe
while latex agglutination test is commonly used in Japan.
The use of different test methods could bring potential
discrepancy in serum PG levels [18].
In this study, all subjects were Chinese Han people in
Hunan who lived in a similar environment, had similar
eating habits and life style, and were of the same race. In
addition, there were no significant differences in age and
sex between patients with different gastric diseases and
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level and PG I/II ratio could indicate the occurrence of
gastric cancer. The optimal cut-off value in this popula-
tion for the diagnosis of gastric cancer was 70 μg/L for
PG I with 82.1% sensitivity and 72.5% specificity, and 6.0
for PG I/II ratio with 82.9% sensitivity and 76.8% specifi-
city. The sensitivity and specificity were 62.1% and 94.2%,
respectively, when combing PG I level and PG I/II ratio.
These results suggest that combined use of low PG I level
and PG I/II ratio are valuable for predicting gastric tu-
mors. While the optimal cut-off value of 70 μg/L for PG I
was similar to that reported in Japan and Korea, the cut-
off value of 6.0 for PG I/II ratio was higher than 3.0 re-
ported in Japan and Korea [15,17]. On the other hand, the
cut-off values were 25 μg/L for PG I and 3.0 for PG I/II in
European countries [16]. The difference between our data
and previous data may be due to the different method-
ology used to detect PG levels, but also could be due to
ethnic background of Chinese.
In addition, in this study we found that gastric ulcer
rarely occurred in this population with serum concentra-
tion of PG I ≤ 100 μg/L or PG II ≤ 10 μg/L, while duodenal
ulcer rarely occurred in those with serum concentration
of PGI ≤ 120 μg/L or PG II ≤ 9 μg/L. These results suggest
that increased serum PG levels are higher risk of peptic
ulcer. It has been reported that hyperpepsinogenaemia
may be considered as a subclinical marker of the genetic
predisposition to duodenal ulcers [19]. Furthermore, we
found that H. pylori infection was associated with in-
creased serum PG levels, in agreement with previous stud-
ies [19-21]. It is known that infection rate of H. pylori is
extremely high in gastric duodenal ulcer. Therefore, serum
PG test is a useful method for the screening and diagnosis
of peptic ulcer.
The limitations of this study should be pointed out.
First, the sample size of this study is relatively small.
Second, we only examined the population who live in
local area of Hunan, midsouth of China. Our results
may not represent the whole Chinese population. There-
fore, further multi-center studies that employ large-scale
subjects are needed to confirm our findings reported in
this study.
Conclusions
Our study suggests that serum PG I level and PG I/II ra-
tio are valuable markers of gastric mucosal changes (as
“serologic biopsy”). Serum PG non-invasive tests could
provide a tool for selecting the population at high risk of
gastric cancer, and reduce the cost and efforts of endos-
copy during large scale gastric cancer screening. How-
ever, because the sensitivity and specificity of PG test are
different in different areas and populations, further stud-
ies are necessary to increase the efficacy of PG test for
gastric disease diagnosis.Competing interest
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